分子影像引导肿瘤免疫治疗新进展
随着肿瘤学、免疫学、影像学研究的发展,免疫治疗已成为继肿瘤传统治疗方法（化学治疗、手术治疗及放射治疗）后的又一种重要的肿瘤治疗方法。其中细胞毒性T淋巴细胞相关抗原4（CTLA-4）和程序性死亡分子1及其配体（PD-1/PD-L1）信号通路是近年来肿瘤免疫治疗研究的热点。目前的CTLA-4和PD1/PDL1药物能够特异性作用于T细胞,增强机体活化T细胞的免疫杀伤功能,在肿瘤治疗中取得了＂突破性＂的效果。但是,并不是所有的患者都对肿瘤免疫治疗有疗效响应,通过核素标记免疫治疗药物分子并利用分子影像学方式进行实时、在体的检测,能够为患者筛选、疗效检测、治疗方案优化、预后评估提供新方法。本综述以目前已有...
Saved in:
| Published in | 肿瘤防治研究 Vol. 45; no. 1; pp. 47 - 51 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
北京大学肿瘤医院暨北京市肿瘤防治研究所,核医学科,恶性肿瘤发病机制及转化研究教育部重点实验室 100142 北京
2018
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1000-8578 |
| DOI | 10.3971/j.issn.1000-8578.2018.17.0971 |
Cover
| Abstract | 随着肿瘤学、免疫学、影像学研究的发展,免疫治疗已成为继肿瘤传统治疗方法（化学治疗、手术治疗及放射治疗）后的又一种重要的肿瘤治疗方法。其中细胞毒性T淋巴细胞相关抗原4（CTLA-4）和程序性死亡分子1及其配体（PD-1/PD-L1）信号通路是近年来肿瘤免疫治疗研究的热点。目前的CTLA-4和PD1/PDL1药物能够特异性作用于T细胞,增强机体活化T细胞的免疫杀伤功能,在肿瘤治疗中取得了＂突破性＂的效果。但是,并不是所有的患者都对肿瘤免疫治疗有疗效响应,通过核素标记免疫治疗药物分子并利用分子影像学方式进行实时、在体的检测,能够为患者筛选、疗效检测、治疗方案优化、预后评估提供新方法。本综述以目前已有的核素标记免疫治疗药物临床分子显像为基点,阐述了近年肿瘤免疫治疗领域的巨大改变,并对分子影像引导肿瘤免疫治疗发展趋势进行展望。 |
|---|---|
| AbstractList | R730.51; 随着肿瘤学、免疫学、影像学研究的发展, 免疫治疗已成为继肿瘤传统治疗方法 (化学治疗、手术治疗及放射治疗) 后的又一种重要的肿瘤治疗方法.其中细胞毒性T淋巴细胞相关抗原4 (CTLA-4) 和程序性死亡分子1及其配体 (PD-1/PD-L1) 信号通路是近年来肿瘤免疫治疗研究的热点.目前的CTLA-4和PD1/PDL1药物能够特异性作用于T细胞, 增强机体活化T细胞的免疫杀伤功能, 在肿瘤治疗中取得了"突破性"的效果.但是, 并不是所有的患者都对肿瘤免疫治疗有疗效响应, 通过核素标记免疫治疗药物分子并利用分子影像学方式进行实时、在体的检测, 能够为患者筛选、疗效检测、治疗方案优化、预后评估提供新方法.本综述以目前已有的核素标记免疫治疗药物临床分子显像为基点, 阐述了近年肿瘤免疫治疗领域的巨大改变, 并对分子影像引导肿瘤免疫治疗发展趋势进行展望. 随着肿瘤学、免疫学、影像学研究的发展,免疫治疗已成为继肿瘤传统治疗方法（化学治疗、手术治疗及放射治疗）后的又一种重要的肿瘤治疗方法。其中细胞毒性T淋巴细胞相关抗原4（CTLA-4）和程序性死亡分子1及其配体（PD-1/PD-L1）信号通路是近年来肿瘤免疫治疗研究的热点。目前的CTLA-4和PD1/PDL1药物能够特异性作用于T细胞,增强机体活化T细胞的免疫杀伤功能,在肿瘤治疗中取得了＂突破性＂的效果。但是,并不是所有的患者都对肿瘤免疫治疗有疗效响应,通过核素标记免疫治疗药物分子并利用分子影像学方式进行实时、在体的检测,能够为患者筛选、疗效检测、治疗方案优化、预后评估提供新方法。本综述以目前已有的核素标记免疫治疗药物临床分子显像为基点,阐述了近年肿瘤免疫治疗领域的巨大改变,并对分子影像引导肿瘤免疫治疗发展趋势进行展望。 |
| Abstract_FL | With the development of oncology, immunology and imaging, tumor immunotherapy has been one of the most important strategies for cancer treatment after the classic tumor therapies (chemotherapy, surgery-therapy and radio-therapy). Among them, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein/protein ligand 1 (anti-PD-1/PD-L1) attract most attention in tumor immunotherapy fields. The CTLA-4 and PD1/PDL1 antibodies can specifically bind and regulate the T cell, enhance the T-cell immune-killer ability to tumors and hold great potential to revolutionize cancer therapy. However, studies have demonstrated the lack of clinical benefit in some patients using immunotherapy. Molecular imaging that based on radio-nuclide labeled immune-therapy antibodies provide a new method for patients selection, response assessment, treatment plan optimization and prognosis assessment by real-time and in-vivo radio-immuno-imaging. This paper based on the existing radio-nuclide labeled immune-therapy antibodies expounds the great change of tumor immunotherapy in the field of molecular imaging in recent years and the research progress of molecular imaging guiding the development of tumor immunotherapy trends. |
| Author | 郭晓轶;刘菲;韩雪迪;朱华;杨志 |
| AuthorAffiliation | 北京大学肿瘤医院暨北京市肿瘤防治研究所、核医学科、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142 |
| AuthorAffiliation_xml | – name: 北京大学肿瘤医院暨北京市肿瘤防治研究所,核医学科,恶性肿瘤发病机制及转化研究教育部重点实验室 100142 北京 |
| Author_FL | ZHU Hua HAN Xuedi LIU Fei YANG Zhi GUO Xiaoyi |
| Author_FL_xml | – sequence: 1 fullname: GUO Xiaoyi – sequence: 2 fullname: LIU Fei – sequence: 3 fullname: HAN Xuedi – sequence: 4 fullname: ZHU Hua – sequence: 5 fullname: YANG Zhi |
| Author_xml | – sequence: 1 fullname: 郭晓轶;刘菲;韩雪迪;朱华;杨志 |
| BookMark | eNo9jz9LAzEYhzNUsNZ-CUGc7nxzyV2SUYr_oODSveRyl3ql5rSHSDsqiovo0iq4uoloXa3006TXj2Gk4vQOz8Pv5VlDFZObFKFNDD4RDG93_awojI8BwOMh434AmPuY-eBoBVX_wSqqF0UWA2AMlDCoIs_e3ti3B_s9sVf3djqy79PF5ax8erHXd-X4df75VY4f5-OPxezZTkbraEXLXpHW_24NtfZ2W40Dr3m0f9jYaXoqFNjjUhAdB1TpVEPIgzSJSBQoIlUklIoSgTnhlDIShXEgHRBMJHESCKw5hYSSGtpazl5Io6XptLv5ed-4h-1hTw8H3d88wC7CmRtLUx3npnOWOfe0n53I_qAdMUpdJgPyA0KgZAw |
| ClassificationCodes | R730.51 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3971/j.issn.1000-8578.2018.17.0971 |
| DatabaseName | 中文科技期刊数据库 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Progress of Molecular Imaging-guided Tumor Immunotherapy |
| DocumentTitle_FL | Progress of Molecular Imaging-guided Tumor Immunotherapy |
| EndPage | 51 |
| ExternalDocumentID | zlfzyj201801011 674411070 |
| GrantInformation_xml | – fundername: 国家重点研发计划数字诊疗装备; 国家自然科学基金面上项目; 北京市自然科学基金重点项目 funderid: (2016YFC0100402); (81676733); (7171002) |
| GroupedDBID | -05 2B. 2C~ 2RA 5XA 5XF 92F 92I 92L ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 GROUPED_DOAJ TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI PSX |
| ID | FETCH-LOGICAL-c591-8a93fb24cfef0582ed6362c3ac69cc6d91838447365b2a2c3979dbd291f840d43 |
| ISSN | 1000-8578 |
| IngestDate | Thu May 29 04:11:41 EDT 2025 Wed Feb 14 10:09:27 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Molecular imaging PD-1/PD-L1信号通路 Biomarker 分子影像 肿瘤免疫治疗 免疫检查点 PD1/PD-L1 pathway 生物标志物 Tumor immunotherapy Immuno-checkpoint |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c591-8a93fb24cfef0582ed6362c3ac69cc6d91838447365b2a2c3979dbd291f840d43 |
| Notes | 42-1241/R With the development of oncology, immunology and imaging, tumor immunotherapy has been one of the most important strategies for cancer treatment after the classic tumor therapies （chemotherapy, surgery-therapy and radio-therapy）. Among them, cytotoxic T lymphocyte-associated protein 4 （CTLA-4） and the programmed cell death protein/protein ligand 1 （anti-PD-1/PD-L1） attract most attention in tumor immunotherapy fields. The CTLA-4 and PD1/PDL1 antibodies can specifically bind and regulate the T cell, enhance the T-cell immune-killer ability to tumors and hold great potential to revolutionize cancer therapy. However, studies have demonstrated the lack of clinical benefit in some patients using immunotherapy. Molecular imaging that based on radio-nuclide labeled immune-therapy antibodies provide a new method for patients selection, response assessment, treatment plan optimization and prognosis assessment by real-time and in-vivo radio-immuno-imaging. This paper based on the existing radio-nuclide labeled |
| PageCount | 5 |
| ParticipantIDs | wanfang_journals_zlfzyj201801011 chongqing_primary_674411070 |
| PublicationCentury | 2000 |
| PublicationDate | 2018 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – year: 2018 text: 2018 |
| PublicationDecade | 2010 |
| PublicationTitle | 肿瘤防治研究 |
| PublicationTitleAlternate | Cancer Research on Prevention and Treatment |
| PublicationTitle_FL | Cancer Research on Prevention and Treatment |
| PublicationYear | 2018 |
| Publisher | 北京大学肿瘤医院暨北京市肿瘤防治研究所,核医学科,恶性肿瘤发病机制及转化研究教育部重点实验室 100142 北京 |
| Publisher_xml | – name: 北京大学肿瘤医院暨北京市肿瘤防治研究所,核医学科,恶性肿瘤发病机制及转化研究教育部重点实验室 100142 北京 |
| SSID | ssib001104370 ssib017477739 ssib051375314 ssib031740888 ssib038074675 ssib048878127 ssj0000602894 ssib058810878 ssib059160193 |
| Score | 2.1013854 |
| Snippet | ... R730.51; 随着肿瘤学、免疫学、影像学研究的发展, 免疫治疗已成为继肿瘤传统治疗方法 (化学治疗、手术治疗及放射治疗) 后的又一种重要的肿瘤治疗方法.其中细胞毒性T淋巴细胞相关抗原4 (CTLA-4) 和程序性死亡分子1及其配体 (PD-1/PD-L1)... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 47 |
| SubjectTerms | PD-1/PD-L1信号通路 免疫检查点 分子影像 生物标志物 肿瘤免疫治疗 |
| Title | 分子影像引导肿瘤免疫治疗新进展 |
| URI | http://lib.cqvip.com/qk/93922X/201801/674411070.html https://d.wanfangdata.com.cn/periodical/zlfzyj201801011 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxRBEB5iBPEiiooxGnKwT2HXefT049g9O0sQ9BQht2UeOwkim6iJ4B48KIoX0Uui4NWbiMarkfyaSfIzrOrpnZ3E9RVYhqK7urq_qmaquren2nFuUDcJ3SJjrTBPkhaVLGnJQsIqJaW-V7hZ7hfmlO8dtniX3loOl6emHzdOLW1upO1sOPG7kpNYFcrArviV7H9YthYKBUCDfeEJFobnP9mYxCERggiGhOoQ6SKhO0R7piogomtKIiJDw9NFOoYmPtFQxYkURFHDDL-OKWFEaRIzooFH2xLJsQQI7WJzaCu1keyR6vbKUYA7SbhEAqQ1ZSqXSGoISXS9O4i8MGqAgr1Bu8D01jnCYjCDROwJ8PjNxrKLApHQRCk7VKXGLCA2GqmnQ0Tc3PWwr2icoaY-MrAp0YqoyKiPEsWtrhX7jR4jg1Di8JXBLKG5mCxQGwknUhlWCYkHVfwIaajVojGAepAcxyw9yya8UVvXYJkIoYv8WMJxWlidKat5zSyPUNY4FRZExyaPEyYfaMP25Y-MLAzB7bTDKmmGHRMZYxXYT0S2RNEFTONF_YVfFdnwq5jAQITVbU0jx1vlET3ygqm8aJWD1cZjVT7i454ewujK06P4di0ez2qKtsfbmBptHOLUB0-H94vhk3vIhLkVvVPOaZ9zD48C334aj5cRHmb8qv0YhNgUnHHtp_COBtrIgQQ-kEOcXIfxoRfwsHErRCiE54px2rwQlmSwsgrqvWCX4f_95gDMCMgZh1iUN_-IEVPCrK4NVh5AoGu-OxwUyWClESIvnXfO2bXtvKpeVBecqeHqRadVvnpZfn5b_tgpn78pd7fKL7uHz_YO3n8sX7w-2P60_-37wfa7_e2vh3sfyp2tS85SN16KFlv2jpZWBjBaIpFBkfo0K_oF4PT7OYOIOAuSjMksY7mEiEFQygMWpn4CFZLLPM196RWCujkNLjvTg7VB_4ozL4JUgsjEDfOUpixIuRCB2-dCwgon89MZZ7ZG2luvUvH0GIflnAdhy4wzb7H37Av6Ue-Ysa_-nWXWOYt0tcV6zZneeLjZvw6Ljo10zmzWzZl58hN4vdCC |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%88%86%E5%AD%90%E5%BD%B1%E5%83%8F%E5%BC%95%E5%AF%BC%E8%82%BF%E7%98%A4%E5%85%8D%E7%96%AB%E6%B2%BB%E7%96%97%E6%96%B0%E8%BF%9B%E5%B1%95&rft.jtitle=%E8%82%BF%E7%98%A4%E9%98%B2%E6%B2%BB%E7%A0%94%E7%A9%B6&rft.au=%E9%83%AD%E6%99%93%E8%BD%B6&rft.au=%E5%88%98%E8%8F%B2&rft.au=%E9%9F%A9%E9%9B%AA%E8%BF%AA&rft.au=%E6%9C%B1%E5%8D%8E&rft.date=2018&rft.pub=%E5%8C%97%E4%BA%AC%E5%A4%A7%E5%AD%A6%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E6%9A%A8%E5%8C%97%E4%BA%AC%E5%B8%82%E8%82%BF%E7%98%A4%E9%98%B2%E6%B2%BB%E7%A0%94%E7%A9%B6%E6%89%80%2C%E6%A0%B8%E5%8C%BB%E5%AD%A6%E7%A7%91%2C%E6%81%B6%E6%80%A7%E8%82%BF%E7%98%A4%E5%8F%91%E7%97%85%E6%9C%BA%E5%88%B6%E5%8F%8A%E8%BD%AC%E5%8C%96%E7%A0%94%E7%A9%B6%E6%95%99%E8%82%B2%E9%83%A8%E9%87%8D%E7%82%B9%E5%AE%9E%E9%AA%8C%E5%AE%A4+100142+%E5%8C%97%E4%BA%AC&rft.issn=1000-8578&rft.volume=45&rft.issue=1&rft.spage=47&rft.epage=51&rft_id=info:doi/10.3971%2Fj.issn.1000-8578.2018.17.0971&rft.externalDocID=zlfzyj201801011 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93922X%2F93922X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzlfzyj%2Fzlfzyj.jpg |